Robert F. Kennedy Jr., Soon to Announce White House Run, Sows ...
Clobetasol Propionate
Clobetasol Propionate Generic Name & Formulations General DescriptionClobetasol propionate 0.05%; crm; oint; gel; soln for scalp application.
How SuppliedContact supplier.
Clobetasol Propionate Indications IndicationsCorticosteroid-responsive dermatoses.
Clobetasol Propionate Dosage and Administration AdultApply thin layer twice daily (AM & PM); max 50g/week or 50mL/week and 2 consecutive weeks' treatment per course.
ChildrenNot recommended.
Clobetasol Propionate Contraindications ContraindicationsDo not use superpotent forms on face, groin, or axillae. Exclude viral disease (eg, chickenpox, measles).
Clobetasol Propionate Boxed WarningsNot Applicable
Clobetasol Propionate Warnings/Precautions Warnings/PrecautionsTreat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use fluorinated steroids longer than 1 week on the face. Avoid abrupt cessation in chronic use. Systemic absorption increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used, and in adults if more than 50g weekly of a high potency product is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. In children). Use caution if applying to face or body folds. Do not use continuously or for prophylaxis. Foams are flammable. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Clobetasol Propionate PharmacokineticsSee Literature
Clobetasol Propionate InteractionsNot Applicable
Clobetasol Propionate Adverse Reactions Adverse ReactionsBurning, stinging, pruritus, erythema, skin atrophy, striae, miliaria, secondary infections, hypopigmentation, folliculitis, hypertrichosis, acneiform eruptions, dermal cracking and fissuring, telangiectasia, contact dermatitis, other local effects, immunosuppression, masks infections, HPA axis suppression (esp. In children).
Clobetasol Propionate Clinical TrialsSee Literature
Clobetasol Propionate Note NotesFormerly known under the brand name Temovate, Temovate-E.
Clobetasol Propionate Patient CounselingSee Literature
Does Clobetasol 17 Propionate Interact With Other Medications?
These medications are not usually taken together. Consult your healthcare professional (e.G., doctor or pharmacist) for more in formation.
Search Drugs Related Drugs
No related drugs found for this medication
Drug Survey
Are you currently using Clobetasol 17 Propionate?This survey is being conducted by the WebMD marketing sciences department.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.
Cipla Gets Exclusive Rights To Market Ophthalmic Drug Across 11 Countries
Taipei: Taiwan-based Formosa Pharmaceuticals has announced an exclusive licensing agreement with Cipla Limited for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007).
Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain following ocular surgery across 11 countries such as India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.
APP13007 is a novel, patent protected and USFDA approved ophthalmic product. It offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid and sustained relief from inflammation and pain. This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits.
"Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected global pharmaceutical brand. We appreciate their recognition and desire to add APP13007 to their rich portfolio of innovative medicines and look forward to working together to provide our novel therapy to ocular surgery patients to their audience." said Erick Co, President and CEO of Formosa Pharmaceuticals.
Commenting on this partnership, Achin Gupta, Global Chief Operating Officer, Cipla said, "The partnership with Formosa Pharmaceuticals marks a significant milestone for Cipla, as it is our first multi-regional licensing agreement in ophthalmology. It reinforces our commitment to bringing cutting-edge treatments to patients worldwide. With exclusive rights to market APP13007 across 11 countries, we are excited to expand access to this innovative therapy and strengthen our ophthalmology portfolio. We look forward to leveraging Cipla's strong commercial presence to make a meaningful impact in post-operative eye care."
Cipla's ophthalmology division is focused on developing therapies and technologies for glaucoma, dry eye disease, ocular infections and retinal diseases. The strategic licensing agreement with Formosa Pharmaceuticals includes upfront payments, royalty milestones, and additional value-driven considerations throughout its term.
Read also: Cipla to invest ZAR 900 million in equity share capital of South Africa subsidiary
Comments
Post a Comment